Papa Medical's Q3 Net Income Plunges Amid Rising Costs, Cash Burn

TL;DR

**Papa Medical's Q3 results are a red flag; strong YTD revenue can't mask the cash burn and profit collapse, making this IPO a risky bet.**

AI Summary

Papa Medical Inc. experienced a significant decline in net income and revenue for the three months ended September 30, 2025, reporting a net loss of $819,923 compared to a net income of $304,471 in the prior year period. Quarterly revenues decreased by 26.1% to $7,368,220 from $9,972,437. However, for the nine months ended September 30, 2025, revenues increased substantially to $39,948,742 from $27,282,305 in 2024, representing a 46.4% growth. Despite this nine-month revenue growth, net income for the nine-month period fell by 43.7% to $590,354 from $1,048,355. The company saw a notable increase in operating expenses, with selling and marketing expenses rising to $1,625,511 for the quarter and $5,272,330 for the nine months, up from $1,201,905 and $3,282,642 respectively. Cash and cash equivalents plummeted from $4,749,842 at December 31, 2024, to $857,529 by September 30, 2025, indicating significant cash burn from operating activities, which used $3,337,162 during the nine-month period. The company also incurred $1,222,960 in deferred offering costs, signaling ongoing IPO preparations.

Why It Matters

This filing reveals a concerning trend for Papa Medical Inc., with a sharp decline in quarterly profitability and significant cash burn, despite strong year-to-date revenue growth. For investors, the negative net income and dwindling cash reserves raise questions about the company's operational efficiency and ability to sustain growth without external financing, especially as it prepares for an IPO. Employees might face uncertainty if financial performance continues to deteriorate. Competitors in the e-cigarette and Hemp cannabinoid E-vapor market could capitalize on Papa Medical's struggles, potentially gaining market share if the company cannot stabilize its profitability and cash flow. The broader market will watch to see if this is a temporary setback or a sign of deeper issues in a competitive industry.

Risk Assessment

Risk Level: high — The company reported a net loss of $819,923 for the three months ended September 30, 2025, a significant reversal from a $304,471 net income in the prior year. Cash and cash equivalents decreased by over 80% from $4,749,842 at December 31, 2024, to $857,529 by September 30, 2025, with net cash used in operating activities totaling $3,337,162 for the nine-month period, indicating severe liquidity challenges.

Analyst Insight

Investors should exercise extreme caution and thoroughly scrutinize Papa Medical's cash flow statements and profitability trends. Given the substantial cash burn and recent net loss, potential investors should demand clear explanations regarding the path to sustained profitability and cash generation before considering any investment, especially in light of its ongoing IPO preparations.

Financial Highlights

debt To Equity

N/A

revenue

$7,368,220

operating Margin

-17.46%

total Assets

$14,292,129

total Debt

$10,722,643

net Income

-$819,923

eps

N/A

gross Margin

19.27%

cash Position

$857,529

revenue Growth

-26.1%

Key Numbers

• $819,923 — Net loss for Q3 2025 (Reversed from a net income of $304,471 in Q3 2024.)
• $7,368,220 — Revenue for Q3 2025 (Decreased by 26.1% from $9,972,437 in Q3 2024.)
• $39,948,742 — Revenue for nine months ended Sept 30, 2025 (Increased by 46.4% from $27,282,305 in the same period of 2024.)
• $590,354 — Net income for nine months ended Sept 30, 2025 (Decreased by 43.7% from $1,048,355 in the same period of 2024.)
• $857,529 — Cash and cash equivalents as of Sept 30, 2025 (Significantly down from $4,749,842 at Dec 31, 2024.)
• $3,337,162 — Net cash used in operating activities for nine months ended Sept 30, 2025 (Increased from $686,321 used in the same period of 2024.)
• $1,222,960 — Deferred offering cost as of Sept 30, 2025 (Increased from $1,060,960 at Dec 31, 2024, indicating ongoing IPO expenses.)
• 20,000,000 — Weighted average shares outstanding (Consistent for both Class A and Class B common stock.)

Key Players & Entities

• Papa Medical Inc. (company) — registrant
• Hua Yao (person) — Chief Financial Officer
• Shenzhen LFS Nebulizer Medical Co., Ltd (company) — related party
• Mr. Jian Hua (person) — principal shareholder of Papa Medical Inc.
• SEC (regulator) — U.S. Securities and Exchange Commission
• PAPA Health Inc. (company) — wholly owned subsidiary
• Cannapresso LAB Inc. (company) — wholly owned subsidiary
• DEUS LAB INC. (company) — wholly owned subsidiary
• QIK. INC. (company) — wholly owned subsidiary
• AirICU INC (company) — wholly owned subsidiary

FAQ

Risk Factors

• Significant Cash Burn and Declining Liquidity [high — financial]: The company's cash and cash equivalents have plummeted from $4,749,842 at the end of 2024 to $857,529 as of September 30, 2025. This is largely due to a net cash outflow from operating activities of $3,337,162 for the nine-month period, a substantial increase from $686,321 in the prior year. This rapid depletion of cash raises concerns about the company's ability to fund ongoing operations and future growth initiatives.
• Deteriorating Profitability Despite Revenue Growth [high — financial]: While nine-month revenues increased by 46.4% to $39,948,742, net income for the same period decreased by 43.7% to $590,354. The third quarter of 2025 saw a net loss of $819,923, a stark reversal from a net income of $304,471 in Q3 2024. This indicates that cost control measures are not keeping pace with revenue generation, leading to margin compression.
• Surge in Operating Expenses [medium — operational]: Operating expenses have significantly increased, with selling and marketing expenses alone rising to $1,625,511 for the quarter and $5,272,330 for the nine months, up from $1,201,905 and $3,282,642 respectively. General and administrative and research and development expenses have also seen substantial increases. This aggressive spending, particularly in sales and marketing, has not translated into proportional profit growth.
• Deferred Offering Costs [medium — financial]: The company has incurred $1,222,960 in deferred offering costs as of September 30, 2025, an increase from $1,060,960 at the end of 2024. These costs are associated with preparations for an Initial Public Offering (IPO). While indicative of strategic growth plans, these costs represent an outflow of capital that could otherwise be used for operations or investment.
• Compliance with Evolving Healthcare Regulations [medium — regulatory]: As a medical company, Papa Medical Inc. is subject to a complex and evolving landscape of healthcare regulations, including those related to patient data privacy (e.g., HIPAA), product safety, and reimbursement policies. Non-compliance can lead to significant fines, legal penalties, and reputational damage, impacting financial performance and operational continuity.
• Intense Competition in the Medical Device/Services Sector [medium — market]: The medical industry is highly competitive, with established players and emerging startups vying for market share. Papa Medical Inc. faces competition from companies offering similar products or services, potentially impacting pricing power, customer acquisition costs, and market penetration. Sustained innovation and effective market strategies are crucial for differentiation.

Industry Context

Papa Medical Inc. operates within the dynamic and competitive healthcare sector, likely focusing on medical devices, services, or technology. This industry is characterized by rapid innovation, stringent regulatory oversight (FDA, HIPAA), and evolving reimbursement models. Key trends include the increasing adoption of telehealth, personalized medicine, and data-driven healthcare solutions. Competition is fierce from both established giants and agile startups, necessitating continuous investment in R&D and market access.

Regulatory Implications

The company must navigate complex healthcare regulations, including those governing product safety, efficacy, and data privacy. Compliance failures can result in severe penalties, product recalls, and reputational damage. Changes in government healthcare policies or reimbursement rates could also significantly impact revenue streams and profitability.

What Investors Should Do

1. Monitor cash burn rate closely.
2. Analyze the drivers of increased operating expenses.
3. Evaluate the progress and likelihood of the IPO.
4. Assess the sustainability of revenue growth.

Key Dates

• 2025-09-30: End of Q3 2025 — Reported a net loss of $819,923 and revenues of $7,368,220, a 26.1% decrease year-over-year. Cash reserves significantly depleted to $857,529.
• 2025-09-30: Nine Months Ended September 30, 2025 — Revenues grew 46.4% to $39,948,742, but net income fell 43.7% to $590,354. Operating cash burn was $3,337,162.
• 2024-12-31: End of Fiscal Year 2024 — Company held $4,749,842 in cash and cash equivalents.

Glossary

Deferred offering cost

Costs incurred in preparation for a public offering of securities, such as an IPO. These costs are capitalized and amortized over the life of the offering or expensed if the offering is abandoned. (Indicates ongoing efforts to raise capital through an IPO, with $1,222,960 capitalized as of September 30, 2025.)

Operating lease liabilities

Obligations arising from lease agreements where the company has the right to use an asset for a specified period, recognized on the balance sheet under accounting standards like ASC 842. (Represents future payments for leased assets, with current liabilities of $1,129,768 and non-current liabilities of $206,470 as of September 30, 2025.)

Weighted average shares outstanding

The average number of outstanding shares of common stock over a period, adjusted for the timing of share issuances or repurchases. Used in EPS calculations. (Stated as 20,000,000, this figure is consistent and relevant for understanding potential dilution and per-share metrics, though EPS is not calculable due to the net loss.)

Advance from customers

Payments received from customers for goods or services that have not yet been delivered or rendered. It represents a liability until the revenue is earned. (A significant liability of $3,566,426 as of September 30, 2025, indicating customer prepayments for future services or products.)

Year-Over-Year Comparison

Compared to the prior year period, Papa Medical Inc. shows a concerning trend of deteriorating profitability despite significant revenue growth over the nine-month period. Quarterly revenue declined by 26.1%, leading to a net loss of $819,923 in Q3 2025, a reversal from a profit in Q3 2024. While nine-month revenues are up 46.4%, net income has fallen 43.7%. Key risks have emerged or intensified, notably the dramatic decrease in cash reserves and a substantial increase in operating expenses, particularly in sales and marketing, indicating a potential shift towards aggressive growth spending at the expense of short-term profitability.

Filing Documents

• ea0265274-10q_papamedical.htm (10-Q) — 1027KB
• ea0265274ex31-1_papamed.htm (EX-31.1) — 11KB
• ea0265274ex31-2_papamed.htm (EX-31.2) — 11KB
• ea0265274ex32-1_papamed.htm (EX-32.1) — 4KB
• ea0265274ex32-2_papamed.htm (EX-32.2) — 4KB
• 0001213900-25-110264.txt ( ) — 6117KB
• ck0002024283-20250930.xsd (EX-101.SCH) — 61KB
• ck0002024283-20250930_cal.xml (EX-101.CAL) — 56KB
• ck0002024283-20250930_def.xml (EX-101.DEF) — 177KB
• ck0002024283-20250930_lab.xml (EX-101.LAB) — 382KB
• ck0002024283-20250930_pre.xml (EX-101.PRE) — 332KB
• ea0265274-10q_papamedical_htm.xml (XML) — 983KB

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS This report contains forward-looking statements regarding our business, financial condition, results of operations and prospects. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements, but are not deemed to represent an all-inclusive means of identifying forward-looking statements as denoted in this report. Additionally, statements concerning future matters are forward-looking Although forward-looking statements in this report reflect the good faith judgment of our management, such statements can only be based on facts and factors currently known by us. Consequently, forward-looking statements are inherently subject to risks and uncertainties and actual results and outcomes may differ materially from the results and outcomes discussed in or anticipated by the forward-looking statements. Factors that could cause or contribute to such differences in results and outcomes include, without limitation, those specifically addressed under Part I, Item 1A, "Risk Factors" and Part II, Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations" of our Registration Statement on Form S-1 filed on August 7, 2025, as declared effective by the SEC on August 12, 2025 and post-effective amendment no. 1 to our Registration Statement on Form S-1 filed on September 29, 2025, as well as the headings "Risks Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in this Form 10-Q and in other reports that we file with the U.S. Securities and Exchange Commission (the "SEC"). You are urged not to place undue reliance on these forward-looking We file reports with the SEC. The SEC maintains a website (www.sec.gov) that contains reports, proxy and information statements, a

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION 1 Item 1.

Financial Statements

Financial Statements 1 Unaudited Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024 1 Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2025 and 2024 2 Unaudited Condensed Consolidated Statements of Changes in Stockholders' Equity for the three and nine months ended September 30, 2025 and December 31, 2024 3 Unaudited Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2025 and December 31, 2024 4 Notes to Unaudited Condensed Consolidated Financial Statements 5 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 26 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 41 Item 4.

Controls and Procedures

Controls and Procedures 41

- OTHER INFORMATION

PART II - OTHER INFORMATION 42 Item 6. Exhibits 42 i PART I - FINANCIAL INFORMATION

-Financial Statements

ITEM 1-Financial Statements PAPA MEDICAL Inc . CONDENSED CONSOLIDATED BALANCE SHEETS As of Notes September 30, 2025 December 31, 2024 (Unaudited) ASSETS Current assets: Cash and cash equivalents $ 857,529 $ 4,749,842 Accounts receivable, net 4 167,963 216,352 Inventories 5 7,443,649 7,429,293 Amounts due from related parties 11 11,000 11,000 Deferred offering cost 1,222,960 1,060,960 Prepayments and other current assets, net 6 1,516,017 1,213,818 Total current assets 11,219,118 14,681,265 Non-current assets: Property, plant and equipment, net 7 1,233,082 1,551,063 Right-of-use assets 8 1,165,931 2,660,535 Deferred tax assets 13 427,758 259,448 Other non-current assets 9 246,240 263,250 Total non-current assets 3,073,011 4,734,296 Total assets $ 14,292,129 $ 19,415,561 LIABILITIES AND EQUITY Current liabilities: Accounts payable $ 1,332,204 $ 2,617,733 Taxes payable 22,184 27,989 Amounts due to related parties 11 3,884,798 4,826,976 Operating lease liabilities, current 8 1,129,768 1,041,197 Advance from customers 3,566,426 4,949,717 Accrued expenses and other current liabilities 10 580,793 1,348,941 Total current liabilities 10,516,173 14,812,553 Non-current liabilities: Operating lease liabilities, non-current 8 206,470 1,623,876 Total non-current liabilities 206,470 1,623,876 Total liabilities $ 10,722,643 $ 16,436,429 Shareholders' equity: Class A Common stock ($ 0.0001 par value; 137,634,560 shares authorized; 7,634,560 shares issued and outstanding as of September 30, 2025 and December 31, 2024* $ 763 $ 763 Class B Common stock ($ 0.0001 par value; 12,365,440 shares authorized; 12,365,440 shares issued and outstanding as of September 30, 2025 and December 31, 2024* 1,237 1,237 Additional paid-in capital 579,544 579,544 Retained earnings 2,987,942 2,397,588 Total shareholders' equity 3,569,486 2,979,132 Total liabilities and equity $ 14,292,129 $ 19,415,561 * The shares data is

View Full Filing

View this 10-Q filing on SEC EDGAR